A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
John D. Hainsworth(Sarah Cannon), Howard A. Burris(Deaconess Hospital), David R. Spigel(Sarah Cannon), Jeffrey R. Infante(Cancer Research Center), Ralph V. Boccia(Center for Cancer and Blood Disorders), Edward Arrowsmith(Center for Cancer and Blood Disorders)
Cited by 87
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k